768 related articles for article (PubMed ID: 27215286)
41. New advancements in CRISPR based gene therapy of Duchenne muscular dystrophy.
Eslahi A; Alizadeh F; Avan A; Ferns GA; Moghbeli M; Reza Abbaszadegan M; Mojarrad M
Gene; 2023 May; 867():147358. PubMed ID: 36914142
[TBL] [Abstract][Full Text] [Related]
42. Evolving Therapeutic Options for the Treatment of Duchenne Muscular Dystrophy.
D'Ambrosio ES; Mendell JR
Neurotherapeutics; 2023 Oct; 20(6):1669-1681. PubMed ID: 37673849
[TBL] [Abstract][Full Text] [Related]
43. CRISPR-mediated Genome Editing Restores Dystrophin Expression and Function in mdx Mice.
Xu L; Park KH; Zhao L; Xu J; El Refaey M; Gao Y; Zhu H; Ma J; Han R
Mol Ther; 2016 Mar; 24(3):564-9. PubMed ID: 26449883
[TBL] [Abstract][Full Text] [Related]
44. Large-scale genome editing based on high-capacity adenovectors and CRISPR-Cas9 nucleases rescues full-length dystrophin synthesis in DMD muscle cells.
Tasca F; Brescia M; Wang Q; Liu J; Janssen JM; Szuhai K; Gonçalves MAFV
Nucleic Acids Res; 2022 Jul; 50(13):7761-7782. PubMed ID: 35776127
[TBL] [Abstract][Full Text] [Related]
45. Gene Editing With CRISPR/Cas9 RNA-Directed Nuclease.
Doetschman T; Georgieva T
Circ Res; 2017 Mar; 120(5):876-894. PubMed ID: 28254804
[TBL] [Abstract][Full Text] [Related]
46. CRISPR Correction of Duchenne Muscular Dystrophy.
Min YL; Bassel-Duby R; Olson EN
Annu Rev Med; 2019 Jan; 70():239-255. PubMed ID: 30379597
[TBL] [Abstract][Full Text] [Related]
47. Current and future delivery systems for engineered nucleases: ZFN, TALEN and RGEN.
Ul Ain Q; Chung JY; Kim YH
J Control Release; 2015 May; 205():120-7. PubMed ID: 25553825
[TBL] [Abstract][Full Text] [Related]
48. CRISPR/Cas9 delivery with one single adenoviral vector devoid of all viral genes.
Ehrke-Schulz E; Schiwon M; Leitner T; Dávid S; Bergmann T; Liu J; Ehrhardt A
Sci Rep; 2017 Dec; 7(1):17113. PubMed ID: 29215041
[TBL] [Abstract][Full Text] [Related]
49. Prime Editing Permits the Introduction of Specific Mutations in the Gene Responsible for Duchenne Muscular Dystrophy.
Happi Mbakam C; Rousseau J; Tremblay G; Yameogo P; Tremblay JP
Int J Mol Sci; 2022 May; 23(11):. PubMed ID: 35682838
[TBL] [Abstract][Full Text] [Related]
50. Gene editing and CRISPR in the clinic: current and future perspectives.
Hirakawa MP; Krishnakumar R; Timlin JA; Carney JP; Butler KS
Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32207531
[TBL] [Abstract][Full Text] [Related]
51. Questions Answered and Unanswered by the First CRISPR Editing Study in a Canine Model of Duchenne Muscular Dystrophy.
Wasala NB; Hakim CH; Chen SJ; Yang NN; Duan D
Hum Gene Ther; 2019 May; 30(5):535-543. PubMed ID: 30648435
[TBL] [Abstract][Full Text] [Related]
52. Therapeutic editing of hepatocyte genome in vivo.
Ruiz de Galarreta M; Lujambio A
J Hepatol; 2017 Oct; 67(4):818-828. PubMed ID: 28527665
[TBL] [Abstract][Full Text] [Related]
53. Delivery and therapeutic applications of gene editing technologies ZFNs, TALENs, and CRISPR/Cas9.
LaFountaine JS; Fathe K; Smyth HD
Int J Pharm; 2015 Oct; 494(1):180-94. PubMed ID: 26278489
[TBL] [Abstract][Full Text] [Related]
54. Adeno-Associated Virus-Mediated Delivery of CRISPR for Cardiac Gene Editing in Mice.
Xu L; Gao Y; Lau YS; Han R
J Vis Exp; 2018 Aug; (138):. PubMed ID: 30124643
[TBL] [Abstract][Full Text] [Related]
55. [Genome-editing: focus on the off-target effects].
He X; Gu F
Sheng Wu Gong Cheng Xue Bao; 2017 Oct; 33(10):1757-1775. PubMed ID: 29082723
[TBL] [Abstract][Full Text] [Related]
56. Research on genodermatoses using novel genome-editing tools.
Lehmann J; Seebode C; Emmert S
J Dtsch Dermatol Ges; 2017 Aug; 15(8):783-789. PubMed ID: 28622433
[TBL] [Abstract][Full Text] [Related]
57. Effective regeneration of dystrophic muscle using autologous iPSC-derived progenitors with CRISPR-Cas9 mediated precise correction.
Hagan M; Ashraf M; Kim IM; Weintraub NL; Tang Y
Med Hypotheses; 2018 Jan; 110():97-100. PubMed ID: 29317080
[TBL] [Abstract][Full Text] [Related]
58. Reading frame correction by targeted genome editing restores dystrophin expression in cells from Duchenne muscular dystrophy patients.
Ousterout DG; Perez-Pinera P; Thakore PI; Kabadi AM; Brown MT; Qin X; Fedrigo O; Mouly V; Tremblay JP; Gersbach CA
Mol Ther; 2013 Sep; 21(9):1718-26. PubMed ID: 23732986
[TBL] [Abstract][Full Text] [Related]
59. Common therapeutic advances for Duchenne muscular dystrophy (DMD).
Salmaninejad A; Jafari Abarghan Y; Bozorg Qomi S; Bayat H; Yousefi M; Azhdari S; Talebi S; Mojarrad M
Int J Neurosci; 2021 Apr; 131(4):370-389. PubMed ID: 32241218
[No Abstract] [Full Text] [Related]
60. Generation of a DMD loss-of-function mutant human embryonic stem cell lines by CRISPR base editing.
Jin H; Fu H; Wang J; Wang Z; Liu J; Han F; Zheng H; Jiang Y
Stem Cell Res; 2024 Apr; 76():103343. PubMed ID: 38428348
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
